Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Gross Margin (2020 - 2025)

Historic Gross Margin for Gyre Therapeutics (GYRE) over the last 7 years, with Q3 2025 value amounting to 94.67%.

  • Gyre Therapeutics' Gross Margin fell 15700.0% to 94.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 95.48%, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of 96.33% for FY2024, which is 4100.0% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Gross Margin is 94.67%, which was down 15700.0% from 95.7% recorded in Q2 2025.
  • Gyre Therapeutics' Gross Margin's 5-year high stood at 96.95% during Q2 2024, with a 5-year trough of 0.89% in Q1 2021.
  • Over the past 5 years, Gyre Therapeutics' median Gross Margin value was 95.49% (recorded in 2023), while the average stood at 64.68%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -822700bps in 2021, then skyrocketed by 959900bps in 2023.
  • Over the past 5 years, Gyre Therapeutics' Gross Margin (Quarter) stood at 0.57% in 2021, then soared by 8352bps to 47.35% in 2022, then soared by 101bps to 95.4% in 2023, then rose by 0bps to 95.78% in 2024, then fell by -1bps to 94.67% in 2025.
  • Its last three reported values are 94.67% in Q3 2025, 95.7% for Q2 2025, and 95.95% during Q1 2025.